EP2041070A1 - Procédé de fabrication d'esters d'acides 3-aminocarboxyliques optiquement actifs - Google Patents

Procédé de fabrication d'esters d'acides 3-aminocarboxyliques optiquement actifs

Info

Publication number
EP2041070A1
EP2041070A1 EP07787131A EP07787131A EP2041070A1 EP 2041070 A1 EP2041070 A1 EP 2041070A1 EP 07787131 A EP07787131 A EP 07787131A EP 07787131 A EP07787131 A EP 07787131A EP 2041070 A1 EP2041070 A1 EP 2041070A1
Authority
EP
European Patent Office
Prior art keywords
acid
formula
alkyl
crystallization
deacylation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP07787131A
Other languages
German (de)
English (en)
Inventor
Christoph JÄKEL
Wolf-Rüdiger KRAHNERT
Rocco Paciello
Wolfgang Siegel
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
BASF SE
Original Assignee
BASF SE
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by BASF SE filed Critical BASF SE
Priority to EP07787131A priority Critical patent/EP2041070A1/fr
Publication of EP2041070A1 publication Critical patent/EP2041070A1/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C227/00—Preparation of compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C227/30—Preparation of optical isomers
    • C07C227/32—Preparation of optical isomers by stereospecific synthesis

Definitions

  • the present invention relates to a process for the preparation of optically active 3-aminocarboxylic acid ester compounds, and their derivatives.
  • the present invention is therefore based on the object to provide a simple and therefore economical process for the preparation of optically active 3-aminocarboxylic acid esters and derivatives thereof.
  • the invention therefore provides a process for the preparation of optically active 3-aminocarboxylic acid ester compounds of the general formula I, and also their ammonium salts,
  • R 1 is alkyl, cycloalkyl, heterocycloalkyl, aryl or hetaryl
  • R 2 is alkyl, cycloalkyl or aryl
  • R 1 and R 2 have the meanings given above and R 3 is hydrogen, alkyl, cycloalkyl or aryl, by addition of an acidic salt former of a deacylation and a subsequent further Enantiomerenanreichtation by crystallization.
  • Another object of the present invention is a process for the preparation of optically active 3-aminocarboxylic acid ester compounds of the general formula I ', as well as their derivatives,
  • R 1 is alkyl, cycloalkyl, heterocycloalkyl, aryl, or hetaryl, and
  • R 2 ' is hydrogen, a cation equivalent M + , alkyl, cycloalkyl or aryl, in which a) a ⁇ -keto ester of the general formula 1.1
  • R 1 and R 2 have the meanings given above,
  • R 1 , R 2 and R 3 have the meanings given above,
  • R 1 , R 2 and R 3 have the meanings given above,
  • Chiral compounds in the context of the present invention are compounds having at least one chiral center (ie at least one asymmetric atom, eg at least one asymmetric C atom or P atom), with chirality axis, Chirality plane or helical turn.
  • chiral catalyst includes catalysts having at least one chiral ligand.
  • a “prochiral compound” is understood to mean a compound having at least one prochiral center.
  • “Asymmetric synthesis” refers to a reaction in which, from a compound having at least one prochiral center, a compound having at least one chiral center, a chiral axis, a plane of chirality, or a helical coil is generated, whereby the stereoisomeric products are formed in unequal amounts.
  • Steps are compounds of the same constitution but of different atomic order in three-dimensional space.
  • Enantiomers are stereoisomers that behave as image to mirror image to each other.
  • R and S are the descriptors of the CIP reaction.
  • the enantiomerically pure compound (ee 100%) is also called "homochiral compound".
  • the process of the invention results in products that are enriched in a particular stereoisomer.
  • the achieved "enantiomeric excess" (ee) is usually at least 3% higher than that of the N-acylated 3-aminocarboxylic acid ester.
  • the achievable ee value with the method is usually at least 98%.
  • Diastereomers are stereoisomers that are not enantiomeric to one another.
  • stereochemical terms listed herein refer to the carbon atom of the respective compounds corresponding to the asymmetric ⁇ -carbon atom in compound I or I '. If further stereocenters are present, they are neglected in the context of the present invention in the designation.
  • alkyl includes straight-chain and branched alkyl groups.
  • it is straight-chain or branched CrC 2 O-alkyl, preferably CrCl 2 alkyl, more preferably d-C ⁇ -alkyl, and especially preferably d-Ce-alkyl groups.
  • alkyl groups are in particular methyl, ethyl, propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, n-pentyl, 2-pentyl, 2-methylbutyl, 3-methylbutyl, 1, 2-dimethylpropyl , 1, 1-dimethylpropyl, 2,2-dimethylpropyl, 1-ethylpropyl, n-hexyl, 2-hexyl, 2-methylpentyl, 3-methylpentyl, 4-methylpentyl, 1, 2-dimethylbutyl, 1, 3-dimethylbutyl, 2 , 3-dimethylbutyl,
  • alkyl also includes substituted alkyl groups which are generally 1, 2, 3, 4 or 5, preferably 1, 2 or 3 and particularly preferably 1 substituent selected from the groups cycloalkyl, aryl, hetaryl, halogen, COOR f , CO " M + and NE can carry 1 E 2 , wherein R f is hydrogen, alkyl, cycloalkyl or aryl, M + is a cation equivalent and E 1 and E 2 are independently hydrogen, alkyl, cycloalkyl or aryl.
  • cycloalkyl for the purposes of the present invention comprises both unsubstituted and substituted cycloalkyl groups, preferably Cs-C ⁇ -cycloalkyl groups, such as cyclopentyl, cyclohexyl or cycloheptyl, which in the case of a substitution, in general 1, 2, 3, 4 or 5, preferably 1, 2 or 3 and particularly preferably 1 substituent, preferably selected from alkyl and the substituents mentioned for alkyl, can carry.
  • heterocycloalkyl in the context of the present invention comprises saturated, cycloaliphatic groups having generally 4 to 7, preferably 5 or 6, ring atoms in which 1 or 2 of the ring carbon atoms are replaced by heteroatoms, preferably selected from the elements oxygen, nitrogen and sulfur and which may optionally be substituted, wherein in the case of a substitution, these heterocycloaliphatic groups 1, 2 or 3, preferably 1 or 2, more preferably 1 substituent selected from alkyl, cycloalkyl, aryl, COOR f , COO " M + and NE 1 E 2 , preferably alkyl, where R f is hydrogen, alkyl, cycloalkyl or aryl, M + is a cation equivalent and E 1 and E 2 are each independently hydrogen, alkyl, cycloalkyl or aryl Heterocycloaliphatic groups are pyrrolidinyl, piperidinyl, 2,2,6,6-tetramethylpiperidinyl, imi
  • aryl for the purposes of the present invention comprises unsubstituted and substituted aryl groups, and is preferably phenyl, ToIyI, XyIyI, mesityl, naphthyl, fluorenyl, anthracenyl, phenanthrenyl or naphthacenyl, particularly preferably phenyl or naphthyl, said aryl groups im
  • a substitution in general 1, 2, 3, 4 or 5, preferably 1, 2 or 3 and particularly preferably 1 substituent selected from the groups alkyl, alkoxy, nitro, cyano or halogen, can carry.
  • heterocycloaromatic groups preferably the groups pyridyl, quinolinyl, acridinyl, pyridazinyl, pyrimidinyl, pyrazinyl, pyrrolyl, imidazolyl, pyrazolyl, indolyl, purinyl, indazolyl, benzotriazolyl , 1, 2,3-triazolyl, 1, 3,4-triazolyl and carbazolyl, these heterocycloaromatic groups in the case of a substitution generally 1, 2 or 3 substituents selected from the groups alkyl, alkoxy, acyl, carboxyl, Carboxylate, -SO 3 H, sulfonate, NE 1 E 2 , alkylene-NE 1 E 2 or halogen, where E 1 and E 2 have the meanings given above.
  • acyl in the context of the present invention represents alkanoyl or aroyl groups having generally 2 to 11, preferably 2 to 8, carbon atoms, for example the acetyl, propanoyl, butanoyl, pentanoyl, hexanoyl, hepta noyl, 2-ethylhexanoyl, 2-propylheptanoyl, benzoyl, naphthoyl or trifluoroacetyl group.
  • Halogen is fluorine, chlorine, bromine and iodine, preferably fluorine, chlorine and bromine.
  • M + represents a cation equivalent, ie a monovalent cation or the single positive charge fraction of a multiple cation. These include z. Li, Na, K, Ca and Mg.
  • R 1 is preferably C 1 -C 6 -alkyl, C 3 -C 7 -cycloalkyl or C 6 -C 4 -aryl, which may optionally be substituted as described above.
  • R 1 is methyl, ethyl, n-propyl, isopropyl, n-butyl, tert-butyl, cyclohexyl or phenyl, especially methyl.
  • R 2 is preferably unsubstituted or substituted C 1 -C 6 -alkyl, C 3 -C 7 -cycloalkyl or C 6 -C 4 -aryl.
  • radicals R 2 are methyl, ethyl, n-propyl, isopropyl, n-butyl, tert-butyl, trifluoromethyl, cyclohexyl, phenyl and benzyl.
  • R 2 is hydrogen, M + , as well as the meanings given for R 2 .
  • R 3 is hydrogen, alkyl, cycloalkyl or aryl, in particular hydrogen, methyl, ethyl, trifluoromethyl, benzyl and phenyl.
  • an enantiomeric mixture of the compounds I.sub.b is subjected to deacylation by addition of an acidic salt-forming agent and subsequent further enantiomeric enrichment by crystallization, and the ammonium salt of a 3-aminocarboxylic acid ester enriched with respect to a stereoisomer is isolated.
  • the process thus enables the preparation of optically active compounds of general formula I, starting from mixtures of isomers of compounds of general formula I.b, as they are obtainable for example from the precursor compounds by conventional asymmetric hydrogenation of enamides.
  • enantiomeric mixtures are used which are already enriched in one enantiomer.
  • the ee value of these mixtures is preferably greater than 75% and particularly preferably greater than 90%.
  • the deacylation is carried out in an alcoholic solvent.
  • An alcoholic solvent used according to the invention is understood as meaning both pure alcohols and solvent mixtures which contain alcohols.
  • these are methanol, ethanol, n-propanol, isopropanol, n-butanol, t-butanol and cyclohexanol, and mixtures thereof with inert solvents, such as aromatics, for example toluene, and chlorinated hydrocarbons, dichloromethane or chloroform ,
  • inert solvents such as aromatics, for example toluene, and chlorinated hydrocarbons, dichloromethane or chloroform
  • R 2 -OH where R 2 has the same meaning as in the product of the formula I or II.
  • ester as solvent or a solvent mixture comprising at least one ester is added for the enantiomeric enrichment by crystallization.
  • the ester is preferably alkyl acetates, in particular alkyl acetates of the formula CH 3 C (O) OR 2 , where R 2 has the meaning given above.
  • R 2 particularly preferably has the same meaning as in the reacted N-acylated 3-aminocarboxylic acid ester of the formula (Ib).
  • the ester is methyl acetate or ethyl acetate.
  • the solvent or solvent mixture used in the deacylation is partially or completely removed by a customary method known to the person skilled in the art, especially by a distillative process.
  • a suitable solvent or solvent mixture especially consisting of one or comprising an ester, is added to the residue for the enantiomeric enrichment by crystallization.
  • the solvent used for the enantiomeric enrichment by crystallization is added to a concentrated (i.e., a saturated or nearly saturated) solution of the 3-aminocarboxylic acid ester compound.
  • the residual content of the solvent used in the deacylation is then further reduced by a process known to the person skilled in the art, preferably by distillation.
  • the residual content of the solvent used in the deacylation is reduced to less than 5%.
  • the deacylation is carried out at a temperature of at least 60 ° C, more preferably at least 75 ° C. For the subsequent crystallization, this temperature can be lowered.
  • the pressure in the deacylation is generally within a range of ambient pressure up to 25 bar. When using alcoholic solvents, the pressure is preferably in a range of 1 to 10 bar.
  • the subsequent crystallization can be carried out at atmospheric pressure.
  • the salt former used for deacylation and for subsequent crystallization is selected from achiral acidic compounds.
  • suitable salt formers are acids which have a greater acid strength than acetic acid in the aqueous medium and form ammonium salts with the saturated .beta.-aminocarboxylic acid esters.
  • the precipitation of the salts and their subsequent isolation leads to an increase in the optical purity.
  • the resulting salts of these salt formers are selected from benzoate, oxalate, phosphate, sulfate, hydrogen oxalate, hydrogen sulfate, formate, lactate, fumarate, chloride, bromide, trifluoroacetate, p-toluenesulfonate and methanesulfonate. Particularly preferred are p-toluenesulfonate and methanesulfonate.
  • p-toluenesulfonate or methanesulfonate is used for the deacylation and subsequent crystallization as salt formers and the alcoholic solvent used for the deacylation comprises a compound of the formula R 2 -OH, where R 2 has the meaning given above.
  • the temperature in the enantiomeric enrichment by crystallization is generally in the range between melting point and boiling point of the solvent or solvent mixture used.
  • the temperature in the course of the crystallization can be increased one or more times and / or lowered to initiate the crystal formation and / or to complete the precipitation of the desired enantiomer.
  • the solid isolated after the enantiomer-enriching crystallization has an ee value of at least 97.0% and in particular greater than 98%.
  • N-acylated 3-aminocarboxylic acid esters with an ee value of 95% are used, ee values of at least 98% are generally achieved after deacylation for the corresponding ammonium salts.
  • the product of the formula I or II obtained in the crystallization can be subjected to a work-up (see the following statements on process steps d) and e)).
  • Another object of the invention relates to a process comprising the reaction steps a) to c) described below and optionally d) and e).
  • a ⁇ -keto ester of formula 1.1 is reacted with at least one carboxamide of the formula R 3 -C (O) NH 2 in the presence of an amidation catalyst to remove the water of reaction to give a 3-aminocarboxylic acid ester of formula Ia implemented (step a.1).
  • step a.1 preference is given in step a.1 to acetamide, propionamide, benzoic acid amide, formamide or trifluoroacetamide, in particular to benzoic acid amide or acetamide.
  • Suitable solvents for step a.1 are those which form a low-boiling azeotrope with water, from which the water of reaction can be removed by separation methods known to those skilled in the art (such as, for example, azeotropic distillation).
  • these are aromatics such as toluene, benzene, etc., ketones such as methyl isobutyl ketone or methyl ethyl ketone, etc., and haloalkanes such as chloroform. Preference is given to using toluene.
  • Suitable amidation catalysts are, for example, acids such as p-toluenesulfonic acid, methanesulfonic acid, sulfuric acid or the like. Preferably, p-toluenesulfonic acid is used.
  • the reaction in process step a.1 preferably takes place at a temperature in the range from 20 to 110.degree. C., particularly preferably from 60 to 90.degree. Particularly preferably, the temperature is above the boiling point of the solvent used under normal conditions.
  • Process step a.1 is usually carried out at a pressure of 0.01 to 1.5 bar, in particular 0.1 to 0.5 bar. If appropriate, the aminocarboxylic acid ester obtained in step a.1 can be purified by customary methods known to the person skilled in the art, eg. B. be subjected to distillation.
  • a ⁇ -ketoester of the formula 1.1 is reacted with aqueous ammonia and then with a carboxylic acid derivative of the formula R 3 -C (O) X to give the N-acylated, ⁇ -unsaturated (Z) -3-aminocarboxylic acid ester (Ia), in which X is halogen or a radical of the formula OC (O) R 4 , in which R 4 has the meaning given above for R 3 (step a.2).
  • the carboxylic acid derivative is preferably selected from carboxylic acid chlorides, wherein X is chlorine and R 3 has the meaning given above, or carboxylic anhydrides, wherein X is OC (O) R 4 and R 4 is preferably the same meaning As R 3 possesses, particularly preferably the carboxylic acid derivatives are acetyl chloride, benzoyl chloride or acetic anhydride.
  • the acylation in step a.2 is preferably carried out at a temperature in the range from 20 ° C. to 120 ° C., more preferably at a temperature in the range from 60 ° C. to 90 ° C.
  • the acylation in step a.2 is carried out in a polar solvent or a mixture of a polar solvent with a non-polar solvent, preferably the polar solvent is a carboxylic acid of the formula R 3 COOH or a tertiary amine, as nonpolar Solvents are particularly suitable haloalkanes and aromatics, particularly preferably used as the solvent acetic acid or triethylamine.
  • the acylation in step a.2 can be carried out using a catalyst, this can be used both in catalytic amounts and stoichiometrically or as a solvent, preferably non-nucleophilic bases, such as tertiary amines, more preferably these are triethylamine and / or di - methylaminopyridine (DMAP).
  • a catalyst this can be used both in catalytic amounts and stoichiometrically or as a solvent, preferably non-nucleophilic bases, such as tertiary amines, more preferably these are triethylamine and / or di - methylaminopyridine (DMAP).
  • the (Z) -3-aminocarboxylic acid ester is obtained as a mixture with the (E) -3-aminocarboxylic acid ester and optionally further acylation products.
  • the (Z) -3-aminocarboxylic acid ester of formula I.a will be isolated by methods known to those skilled in the art. A preferred method is separation by distillation.
  • the ⁇ -unsaturated (Z) -3-aminocarboxylic acid ester compounds of the formula Ia obtained in step a can subsequently undergo enantioselective hydrogenation in the presence of a chiral hydrogenation catalyst to give a enantiomerically enriched enantiomeric mixture of simply N-acylated ⁇ -aminocarboxylic acid esters of the general formula (Ib) be subjected.
  • the hydrogenation catalyst used is at least one complex of a transition metal of groups 8 to 11 of the Periodic Table of the Elements, which comprises at least one chiral, phosphorus atom-containing compound as ligand.
  • the hydrogenation is preferably carried out using a chiral hydrogenation catalyst which is capable of hydrogenating the ⁇ -unsaturated, N-acylated 3-aminocarboxylic acid ester (La) used, with preference for the desired isomer.
  • the compound of the formula Ib obtained in step b) preferably has an ee value of at least 75%, particularly preferably at least 90%, after the asymmetric hydrogenation.
  • the ee value of the compound 1b is preferably at least 75%.
  • the process according to the invention preferably allows the enantioselective hydrogenation at substrate / catalyst ratios (s / c) of at least 1000: 1, particularly preferably at least 5000: 1 and in particular at least 15000: 1.
  • the transition metal is selected from Ru, Rh, Ir, Pd or Pt.
  • catalysts based on Rh and Ru are especially preferred.
  • the phosphorus-containing compound used as ligand is preferably selected from bidentate and polydentate phosphine, phosphinite, phosphonite, phosphoramidite and phosphite compounds.
  • catalysts which have at least one ligand selected from compounds of the following formulas,
  • Ar is optionally substituted phenyl, preferably Toyl or Xylyl.
  • bidentate compounds of the aforementioned classes of compounds are particularly preferred.
  • P-chiral compounds such as DuanPhos, TangPhos or Binapine are preferred.
  • Suitable chiral ligands which coordinate to the transition metal via at least one phosphorus atom are known to the person skilled in the art and are commercially available, for example, from Chiral Quest ((Princeton) Inc., Monmouth Junction, NJ). The naming of the previously exemplified chiral ligands corresponds to their commercial designation.
  • Chiral transition metal complexes can be prepared in a manner known to the person skilled in the art (for example Uson, Inorg. Chim. Acta 73, 275 1983, EP-A-0 158 875, EP-A-437 690) by reacting suitable ligands with complexes of the metals, containing labile or hemilabile ligands.
  • NBD norbornadiene
  • Preference is given to [Rh (COD) Cl] 2 , [Rh (COD) 2 ] IX, Rh (acac) (CO) 2 , RuCl 2 (COD), Ru (COD) (methallyl) 2 , Ru (Ar) Cl 2 , Ar aryl, both unsubstituted and substituted, and the corresponding systems with NBD instead of COD.
  • Particularly preferred are [Rh (COD) 2 )] X and [Rh (NBD) 2 ) IX.
  • X can be any anion known to those skilled in the art and generally useful in asymmetric synthesis.
  • Examples of X are halogens such as Cl “ , Br “ or I “ , BF 4 “ , CIO 4 “ , SbF 6 “ , PF 6 “ , CF 3 SO 3 “ , BAr 4 " .
  • Preferred for X are BF 4 “ , PF 6 “ , CF 3 SO 3 " , SbF 6 " .
  • the chiral transition metal complexes can either be generated in situ before the actual hydrogenation reaction in the reaction vessel or else be generated separately, isolated and then used. It may happen that at least one solvent molecule attaches to the transition metal complex.
  • the customary solvents for example methanol, diethyl ether, tetrahydrofuran (THF), dichloromethane, etc.
  • THF tetrahydrofuran
  • dichloromethane dichloromethane
  • the hydrogenation step (step b) of the process according to the invention is carried out usually at a temperature from -10 to 150 0 C, preferably at O to 120 0 C and particularly preferably at 10 to 70 0 C.
  • the hydrogen pressure can be varied within a range between 0.1 bar and 600 bar. This is preferably in a pressure range of 0.5 to 20 bar, more preferably between 1 to 10 bar.
  • Suitable solvents for the hydrogenation reaction of enamides 1a are all solvents known to those skilled in the art for asymmetric hydrogenation. Preferred solvents are lower alkyl alcohols such as methanol, ethanol, isopropanol, as well as toluene, THF, ethyl acetate. In the process according to the invention, ethyl acetate or THF is particularly preferably used as the solvent.
  • the hydrogenation catalysts (or pre-catalysts) described above can also be suitably, for. B. by attachment via suitable as anchor groups functional groups, adsorption, grafting, etc. to a suitable carrier, eg. Example of glass, silica gel, resins, polymer carriers, etc., are immobilized. They are then also suitable for use as solid phase catalysts.
  • a suitable carrier eg. Example of glass, silica gel, resins, polymer carriers, etc.
  • the catalyst consumption can be further reduced by these methods.
  • the catalysts described above are also suitable for a continuous reaction, z. B. after immobilization, as described above, in the form of Festphasenkatalysato- reindeer.
  • the hydrogenation in stage b is carried out continuously.
  • the continuous hydrogenation can be carried out in one or preferably in several reaction zones. Multiple reaction zones may be formed by multiple reactors or by spatially distinct regions within a reactor. When using multiple reactors may each be the same or different reactors. These may each have the same or different mixing characteristics and / or be subdivided by internals one or more times.
  • the reactors can be interconnected as desired, z. B. parallel or in series.
  • Suitable pressure-resistant reactors for the hydrogenation are known to the person skilled in the art. These include the commonly used reactors for gas-liquid reactions, such. B. tubular reactors, tube bundle reactors, stirred tank, gas circulation reactors, bubble columns, etc., which may be filled or divided by internals.
  • step c) reference is made to the statements made at the outset for the crystallization by adding an acidic salt former.
  • the ammonium salts isolated in the enantiomer-enriching crystallization can be subjected to a further work-up. This is how it is for example, to release the optically active compound of formula I, the product of the crystallization with a suitable base, preferably NaHC ⁇ 3 , NaOH, KOH bring into contact. In a suitable procedure, the product of the crystallization is dissolved or suspended in water and then the pH is adjusted by base addition to about 8 to 12, preferably about 10. To isolate the free 3-aminocarboxylic acid ester, it is possible to add the basic solution or suspension with a suitable organic solvent, e.g. Example, an ether, such as methyl butyl ether, a hydrocarbon or hydrocarbon mixture, for.
  • a suitable organic solvent e.g. Example, an ether, such as methyl butyl ether, a hydrocarbon or hydrocarbon mixture, for.
  • alkane such as pentane, hexane, heptane, or an alkane mixture, ligroin or petroleum ether, or aromatics, such as toluene to extract.
  • a preferred extractant is toluene.
  • the 3-aminocarboxylic acid esters may be derivatized using methods known to those skilled in the art. Possible derivatizations include, for example, saponification of the ester or stereoselective reduction of the carboxyl carbon to an optically active alcohol.
  • derivatives of compounds of formula I 'according to the invention include, for example, ammonium salts of 3-aminocarboxylic acid esters, free carboxylic acids wherein R 2 is hydrogen, salts of free carboxylic acid wherein R 2 is M + , and optically active 3-aminoalcohols.
  • the process described above is used to prepare optically active compounds of the formula II, or their ammonium salts, with the following absolute configuration, or for the preparation of the enantiomers of these compounds or salts,
  • R 2 is C 1 -C 6 alkyl.
  • step b) From a according to step b) obtained solution of (R) -N-acetyl-3-aminobutter- acid methyl ester (37.5 g) in THF (43 mL), the solvent was removed under reduced pressure at a temperature of 50 ° C. The residue was taken up in methanol (94 mL) with p-toluenesulfonic acid monohydrate (53.8 g). mixed and stirred for 12 h at 100 ° C under autogenous pressure. After cooling the reaction solution and venting, the methanol was removed under reduced pressure at 50 ° C. The residue was treated at 50 ° C with methyl acetate (1 12 ml_) and then slowly cooled to 0-5 ° C. The precipitated product was isolated by filtration, washed with cold methyl acetate and then dried in vacuo.
  • the structure of the compound was verified by NMR spectroscopy.
  • the content of the compound was determined by titration with a base.
  • the enantiomeric purity was determined after derivatization by gas chromatography on a chiral phase.
  • the derivatization of amino acids and their derivatives to determine the enantiomeric purity is known in the art.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Catalysts (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)

Abstract

Procédé de fabrication de composés d'esters d'acides 3-aminocarboxyliques optiquement actifs, consistant à soumettre un mélange énantiomère d'un ester d'acide 3-aminocarboxylique à N-acylation simple, enrichi avec un énantiomère, à une désacylation par addition d'un agent acide de formation de sels, puis à un enrichissement en énantiomère ultérieur par cristallisation.
EP07787131A 2006-07-06 2007-07-05 Procédé de fabrication d'esters d'acides 3-aminocarboxyliques optiquement actifs Withdrawn EP2041070A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP07787131A EP2041070A1 (fr) 2006-07-06 2007-07-05 Procédé de fabrication d'esters d'acides 3-aminocarboxyliques optiquement actifs

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP06116717 2006-07-06
PCT/EP2007/056843 WO2008003761A1 (fr) 2006-07-06 2007-07-05 Procédé de fabrication d'esters d'acides 3-aminocarboxyliques optiquement actifs
EP07787131A EP2041070A1 (fr) 2006-07-06 2007-07-05 Procédé de fabrication d'esters d'acides 3-aminocarboxyliques optiquement actifs

Publications (1)

Publication Number Publication Date
EP2041070A1 true EP2041070A1 (fr) 2009-04-01

Family

ID=38610670

Family Applications (1)

Application Number Title Priority Date Filing Date
EP07787131A Withdrawn EP2041070A1 (fr) 2006-07-06 2007-07-05 Procédé de fabrication d'esters d'acides 3-aminocarboxyliques optiquement actifs

Country Status (5)

Country Link
US (1) US20090299089A1 (fr)
EP (1) EP2041070A1 (fr)
JP (1) JP5566103B2 (fr)
CN (1) CN101484414B (fr)
WO (1) WO2008003761A1 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102008015773A1 (de) * 2008-03-26 2009-10-01 Albert-Ludwigs-Universität Freiburg Verfahren zur decarboxylativen Hydroformylierung alpha,beta-ungesättigter Carbonsäuren
US20130005002A1 (en) 2009-09-25 2013-01-03 Basf Se Amidase and use thereof for producing 3-aminocarboxylic acid esters

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3849480A (en) * 1968-09-09 1974-11-19 Monsanto Co Catalytic asymmetric hydrogenation
US4261919A (en) * 1968-09-09 1981-04-14 Monsanto Company Catalytic asymmetric hydrogenation
JP3493206B2 (ja) * 1993-03-19 2004-02-03 ダイセル化学工業株式会社 光学活性β−アミノ酸類の製法
EP0967015B1 (fr) * 1998-06-19 2005-01-12 Degussa AG Utilisation de ligands ferrocenyl pour l'hydrogénation catalytique énantioselective
DE10107528B4 (de) * 2001-02-17 2006-05-11 Chiroblock Gmbh Verfahren zur Herstellung der Enantiomere der 2-substituierten beta-Aminosäuren
DE10148551A1 (de) * 2001-10-01 2003-04-10 Bayer Ag Chirale Monophosphorverbindungen
US7105702B2 (en) * 2001-11-09 2006-09-12 The Penn State Research Foundation P-chiral phospholanes and phosphocyclic compounds and their use in asymmetric catalytic reactions
US7169953B2 (en) * 2001-11-09 2007-01-30 The Penn State Research Foundation P-chiral phospholanes and phosphocyclic compounds and their use in asymmetric catalytic reactions
ES2544579T3 (es) * 2002-07-30 2015-09-01 Takasago International Corporation Procedimiento de producción de un beta-aminoácido ópticamente activo
JP4368632B2 (ja) * 2002-07-30 2009-11-18 高砂香料工業株式会社 光学活性β−アミノ酸類の製造方法
US7626034B2 (en) * 2003-09-18 2009-12-01 Takasago International Corporation Asymmetric reductive amination of keto acid derivatives for producing amino acid derivatives
US20050159604A1 (en) * 2004-01-15 2005-07-21 The Penn State Research Foundation Asymmetric hydrogenation of alpha-amino carbonyl compounds

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO2008003761A1 *

Also Published As

Publication number Publication date
CN101484414A (zh) 2009-07-15
WO2008003761A1 (fr) 2008-01-10
CN101484414B (zh) 2012-11-21
JP5566103B2 (ja) 2014-08-06
US20090299089A1 (en) 2009-12-03
JP2009542603A (ja) 2009-12-03

Similar Documents

Publication Publication Date Title
DE60102356T2 (de) Asymmetrische synthese von pregabalin
DE602005002253T2 (de) C1-symmetrische bisphosphinliganden und deren verwendung bei der asymmetrischen synthese von pregabalin
EP0643065B1 (fr) Nouvelles bisphosphines pour catalyseurs d'hydrogénation asymétrique
EP2459579B1 (fr) Composés phosphine-borane contenant des groupes imidazole et procédé de production de composés phosphorés contenant des groupes imidazole
EP0104375A1 (fr) Dérivés biphényliques contenant du phosphore et leur utilisation pour l'hydrogénation asymétrique et la migration énantiosélective d'hydrogène
WO2008132057A1 (fr) Procédé pour produire des composés carbonyle optiquement actifs
EP2254895A1 (fr) Composés de phosphore contenant des groupes imidazole
DE69009237T2 (de) Verfahren zur Herstellung von optisch aktiven Estern der 6-t-Butoxy-3,5-dihydroxyhexansäure.
DE69521605T2 (de) Optisch aktive diphosphine und herstellungsverfahren durch auftrennung der racematmischung
WO2007147897A1 (fr) Procédé de fabrication de dérivés de 2-halogéno-1-phényléthanol optiquement actifs et produits obtenus par ce procédé
DE102004052040A1 (de) Liganden zur asymmetrischen Hydroformylierung
EP2041070A1 (fr) Procédé de fabrication d'esters d'acides 3-aminocarboxyliques optiquement actifs
EP1861352B1 (fr) Procede pour produire des derives d'acide propionique 3-phenyle optiquement actifs et produits reactionnels en decoulant
WO2011036233A1 (fr) Amidase et son utilisation pour la production d'esters d'acide 3-aminocarboxilique
EP0744401B1 (fr) Procédé pour la préparation des dérivés de l'acide 2-pipérazinique optiquement actif
DE69813297T2 (de) Asymmetrische hydrierung
WO2005049570A1 (fr) Procede de synthese de piperidines optiquement actives par hydrogenation de pyridines optiquement actives
DE3889441T2 (de) Katalytisches Verfahren zur Herstellung von optisch aktivem Threonin.
EP0512415B1 (fr) Procédé pour la préparation enantiosélective des dérivés de 2(R) benzyl succinamide
DE60009518T2 (de) Substituierte cyclopentene, verfahren zu deren herstellung und deren verwendungals chirale gerüste
DE102008033165A1 (de) Verfahren zum Herstellen eines optisch aktiven ß-Hydroxycarbonsäurederivats
DE102005012408A1 (de) Verfahren zur Herstellung von optisch aktiven 3-Phenylpropionsäurederivaten und Folgeprodukten davon
DE69914889T2 (de) Asymmetrische hydrierung
US6207853B1 (en) Homogeneous asymmetric hydrogenation using phosphine ligands of transition metals
DE60105250T2 (de) Herstellungsverfahren zur 2-Cyclohexyl-2-hydroxy-Phenylessigsäure, Zwischenprodukt dafür und Herstellungsverfahren davon

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20090206

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC MT NL PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL BA HR MK RS

17Q First examination report despatched

Effective date: 20120514

DAX Request for extension of the european patent (deleted)
GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

INTG Intention to grant announced

Effective date: 20151009

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20160220